ICS Members Only
Join ICS Sign in
{{CC.VideoPaywallHeaderText}}
{{CC.VideoPaywalButtonText}} Sign in Sign in
{{CC.VideoPaywallHeaderText}}
{{CC.VideoPaywalButtonText}} Sign in

To register for this workshop please email reg_ics22@kenes.com

{{CC.VideoPaywallHeaderText}}
Purchase Gold Pass Register Sign in
Prefer to watch at your own pace, catch up on what you missed or re-watch your favourite sessions?
Extend your access to all state of the art and scientific meeting content for an extra three months, until 13 December 2022.

To purchase the gold pass please email reg_ics22@kenes.com
Restricted Video
Sign in
W17 Targeting Neurotrophin and Nitric Oxide Signalling to Promote Recovery and Ameliorate Neurogenic Bladder Dysfunction following Spinal Cord Injury—Mechanistic Concepts and Clinical Implications
Home

Targeting Neurotrophin and Nitric Oxide Signalling to Promote Recovery and Ameliorate Neurogenic Bladder Dysfunction following Spinal Cord Injury—Mechanistic Concepts and Clinical Implications

  • Workshop 17
  • Thursday 8th September 2022
  • 07:30 - 09:00 CEST
  • Hall K1/2. Capacity: 400
  • In-Person and online attendees
  • ICS Members OnlyRestricted Video
26/01/2023 23:03:13

Workshop Schedule

Karl-Erik Andersson
Anthony John Kanai
Christopher Henry Fry
Naoki Yoshimura

Aims & Objectives

Advanced
90 minutes
Neurourology
Pure and Applied Science / Translational
Spinal Cord Contusion Detrusor-sphincter dyssynergia detrusor overactivity
Urology, Urogynaecology and Female & Functional Urology, Bowel Dysfunction, Pure and Applied Science

Spinal cord injury (SCI) causes impairment of mobility and neurogenic detrusor overactivity (NDO) that contribute to a decreased quality of life. This workshop will describe: i) the current state-of-the-art management of lower urinary tract (LUT) dysfunction associated with SCI; ii) the pathophysiology of this dysfunction; and iii) the therapeutic potential of three pharmacological agents to promote functional LUT recovery after SCI. These agents are: LM11A-31, a neurotrophin receptor modulator; LM22B-10, an agent that promotes neuronal growth; and cinaciguat, a soluble guanlyate cyclase activator that supports repair of spinal lesions. LM11A-31 and cinaciguat have passed human safety tests and may readily transition to clinical trials.